A phase II dose-ranging study of mirabegron in patients with overactive bladder

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3AE0103853" target="_blank" >RIV/00843989:_____/13:E0103853 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00192-013-2042-x" target="_blank" >http://dx.doi.org/10.1007/s00192-013-2042-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00192-013-2042-x" target="_blank" >10.1007/s00192-013-2042-x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A phase II dose-ranging study of mirabegron in patients with overactive bladder

Popis výsledku v původním jazyce

Mirabegron is a potent and selective beta(3)-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. Patients completed a single-blinded, 2-week placebo run-in period followed by 12 weeks of randomized (n = 928) double-blinded treatment with mirabegron oral controlled absorption system (OCAS) 25, 50, 100, or 200 mg once-daily (QD), placebo or tolterodine extended release (ER) 4 mg QD. The primary endpoint was change from baseline to end-of-treatment in mean number of micturition episodes/24 h. Secondary endpoints included changes in mean volume voided per micturition; mean number of urinary incontinence, urgency urinary incontinence, and urgency episodes/24 h; severity ofurgency; nocturia; and quality of life measures. Safety parameters included vital signs, adverse events, laboratory tests, electrocardiogram measurements and post-void residual volume. Mirabegron 25, 50, 100, and 200 mg resulted in dose-

Název v anglickém jazyce

A phase II dose-ranging study of mirabegron in patients with overactive bladder

Popis výsledku anglicky

Mirabegron is a potent and selective beta(3)-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. Patients completed a single-blinded, 2-week placebo run-in period followed by 12 weeks of randomized (n = 928) double-blinded treatment with mirabegron oral controlled absorption system (OCAS) 25, 50, 100, or 200 mg once-daily (QD), placebo or tolterodine extended release (ER) 4 mg QD. The primary endpoint was change from baseline to end-of-treatment in mean number of micturition episodes/24 h. Secondary endpoints included changes in mean volume voided per micturition; mean number of urinary incontinence, urgency urinary incontinence, and urgency episodes/24 h; severity ofurgency; nocturia; and quality of life measures. Safety parameters included vital signs, adverse events, laboratory tests, electrocardiogram measurements and post-void residual volume. Mirabegron 25, 50, 100, and 200 mg resulted in dose-

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International urogynecology journal

ISSN

0937-3462

e-ISSN

—

Svazek periodika

24

Číslo periodika v rámci svazku

n. 9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

"p. 1447-1458"

Kód UT WoS článku

000323432600006

EID výsledku v databázi Scopus

—